Edition:
United Kingdom

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

0.69USD
5:43pm BST
Change (% chg)

$-0.02 (-2.39%)
Prev Close
$0.71
Open
$0.70
Day's High
$0.71
Day's Low
$0.65
Volume
10,115
Avg. Vol
61,222
52-wk High
$17.90
52-wk Low
$0.52

Latest Key Developments (Source: Significant Developments)

Sienna Biopharmaceuticals To Explore Financial, Strategic Alternatives
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ENGAGES COWEN TO EXPLORE FINANCIAL AND STRATEGIC ALTERNATIVES.SIENNA BIOPHARMACEUTICALS INC - DOES NOT INTEND TO INITIATE ITS PLANNED PHASE 3 TRIALS OF SNA-120 UNTIL COMPANY SECURES SUFFICIENT ADDITIONAL CAPITAL.SIENNA BIOPHARMACEUTICALS - WILL CONTINUE TO EXPLORE CAPITAL RAISING TO ENABLE INITIATION OF ITS PLANNED PHASE 3 PIVOTAL CLINICAL TRIALS FOR SNA-120.  Full Article

Sienna Biopharmaceuticals Qtrly Net Loss $0.67
Wednesday, 8 May 2019 

May 8 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.QTRLY NET LOSS, BASIC AND DILUTED $0.67.CASH BURN DURING THREE MONTHS ENDED MAR. 31, 2019 WAS APPROXIMATELY $12.8 MILLION.SIENNA'S CASH AND CASH EQUIVALENTS AS OF MAR. 31, 2019 TOTALED APPROXIMATELY $57.2 MILLION.  Full Article

Sienna Biopharmaceuticals Promotes Alexander Azoy To CFO
Thursday, 21 Mar 2019 

March 21 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS PROMOTES ALEXANDER AZOY TO CHIEF FINANCIAL OFFICER AND APPOINTS SEAN ANDREWS TO LEADERSHIP TEAM AS VICE PRESIDENT, INVESTOR RELATIONS.SIENNA BIOPHARMACEUTICALS INC - AZOY WILL SUCCEED JOHN SMITHER AS CFO.  Full Article

Sienna Biopharmaceuticals Reports Q4 Loss Per Share Of $0.93
Thursday, 14 Mar 2019 

March 14 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.93.SIENNA BIOPHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS AS OF DEC. 31, 2018, TOTALED APPROXIMATELY $48.5 MILLION.  Full Article

Arch Venture Fund VIII Reports 19.9 Percent Stake In Sienna Biopharmaceuticals Inc
Thursday, 7 Mar 2019 

March 6 (Reuters) - Sienna Biopharmaceuticals Inc ::ARCH VENTURE FUND VIII REPORTS 19.9 PERCENT STAKE IN SIENNA BIOPHARMACEUTICALS INC AS OF FEB 22 - SEC FILING.  Full Article

Sienna Biopharmaceuticals Says Public Offering Of 8 Mln Common Shares Priced At $2.50 Per Share
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.00 MILLION COMMON SHARES PRICED AT $2.50PER SHARE.  Full Article

Sienna Biopharma Announces Proposed Public Offering Of Common Stock
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Sienna Biopharmaceuticals Says Implemented Corporate Restructuring To Focus Co's Resources On SNA-120
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS - ON JAN 2, IMPLEMENTED CORPORATE RESTRUCTURING TO FOCUS CO'S RESOURCES ON LEAD PRODUCT CANDIDATE, SNA-120 - SEC FILING.SIENNA BIOPHARMACEUTICALS - CORPORATE RESTRUCTURING RESULTED IN REDUCTION IN FORCE TO REDUCE OPERATIONAL COSTS AND PRESERVE CAPITAL.SIENNA BIOPHARMACEUTICALS - RESTRUCTURING WILL RESULT IN ELIMINATION OF 20 POSITIONS, OR ABOUT 34% OF CO'S WORKFORCE.SIENNA BIOPHARMACEUTICALS - RESTRUCTURING IS EXPECTED TO BE SUBSTANTIALLY COMPLETE BY END OF Q1 OF 2019.SIENNA BIOPHARMACEUTICALS - CO'S RESEARCH TEAM BASED IN IVREA, ITALY IS NOT AFFECTED BY RESTRUCTURING.SIENNA BIOPHARMACEUTICALS - ESTIMATES WILL INCUR ONE-TIME EMPLOYEE BENEFITS & SEVERANCE CHARGE OF ABOUT $0.8 MILLION IN Q1 2019 RELATED TO RESTRUCTURING.SIENNA BIOPHARMACEUTICALS - RESTRUCTURING IS EXPECTED TO REDUCE PLANNED OPERATING EXPENSES BY ABOUT 50%, EXCLUDING ONE-TIME CHARGES.  Full Article

Sienna Biopharmaceuticals Announces Plans To Initiate Phase 3 Psoriasis Trials In Second Half Of 2019
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES ITS TOPICAL, NON-STEROIDAL TRKA INHIBITOR SNA-120 (0.05%) DEMONSTRATED SIGNIFICANT IMPACT ON PSORIASIS IN PHASE 2B STUDY AND PLANS TO INITIATE PHASE 3 PSORIASIS TRIALS IN SECOND HALF OF 2019.SIENNA BIOPHARMACEUTICALS INC - SNA-120 WAS WELL TOLERATED WITH FEW TREATMENT-RELATED ADVERSE EVENTS.SIENNA BIOPHARMACEUTICALS INC - SUBJECTS ACHIEVED 58% IMPROVEMENT IN ITCH FROM BASELINE ON I-NRS VERSUS 55% WITH VEHICLE (NOT STATISTICALLY SIGNIFICANT).SIENNA BIOPHARMACEUTICALS INC - 27% OF SUBJECTS ACHIEVED 75% REDUCTION IN PASI SCORE (PASI 75) VERSUS 13% WITH VEHICLE.SIENNA BIOPHARMACEUTICALS INC - 29% OF SUBJECTS ACHIEVED TWO-GRADE IMPROVEMENT ON IGA AND 'CLEAR' OR 'ALMOST CLEAR' SKIN VERSUS 13% WITH VEHICLE.SIENNA BIOPHARMACEUTICALS INC - PHASE 2 STUDY EXPECTED TO BEGIN SECOND HALF 2019.SIENNA BIOPHARMACEUTICALS INC - DID NOT MEET OUR PRIMARY ENDPOINT ON PRURITUS.  Full Article

Sienna Biopharmaceuticals reports third quarter results
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS® REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC - QTRLY NET LOSS PER SHARE $0.82.SIENNA BIOPHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS AS OF SEPT. 30, 2018, TOTALED APPROXIMATELY $64.0 MILLION.  Full Article